Mumbai (Maharashtra) [India], March 15 (ANI/NewsVoir): Alkem Laboratories Ltd. (Alkem), one of India's leading pharmaceutical formulation development, manufacturing, and marketing companies in India, announced the launch of Brivasure, an affordable anti-epileptic drug for the treatment of Epilepsy in India. * Epilepsy is a common neurological disorder. Of the 70 million persons with epilepsy (PWE) worldwide, nearly 12 million PWE are expected to reside in India; which contributes to nearly one-sixth of the global burden.1 * Brivaracetam has shown promise in patients with epilepsy whose seizures persist despite adequate treatment. The drug offers improved seizure control with minimal safety risks for patients with epilepsy2 * Alkem Laboratories Limited has introduced brand Brivasure, the brand of Brivaracetam, at an affordable price in India.